Alberto García-Vadillo

Alberto García-Vadillo

Auto-generated profile, based on publicly available information

Alberto García-Vadillo

Rheumatology Department, Hospital Universitario La Princesa, Madrid, Spain

Research Focus & Metrics

Academic Career Length

43Years (1984-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 July 2019 in Journal of Orthopaedic Surgery and Research
Verified
Journal Article
Open access
PDF file
OGOlalla Guzon-Illescas
Olalla Guzon-Illescas
EPElia Pérez
Elia Pérez
NVNatalia Crespí Villarias
Natalia Crespí Villarias
FDFrancisco Javier Quirós Donate
Francisco Javier Quirós Donate
MPMarina Peña
Marina Peña
Ramón MazzucchelliRamón Mazzucchelli
Ramón Mazzucchelli
It is known that mortality after hip fracture increases compared to the general population; the trend in mortality is a controversial issue. The objective of this study is to examine incidence, trends, and factors associated with mortality in patients with osteoporotic hip fractures. This is a retrospective cohort study that uses the Registry for Hospital Discharges of the National Health System of our hospital. Patients older than 45 having an osteoporotic hip fracture between 1999 and 2015 were identified. Demographic data and comorbidities were obtained. A survival analysis was performed (Cox regression and Kaplan-Meier). Incidence rate, standardized death rate (SDR), trend (Poisson regression), and risk (hazard ratio) were calculated. During 1999–2015, in our hospital, there were a total of 3992 patients admitted due to osteoporotic hip fracture. Out of these 3992 patients, 3109 patients (77.9%) were women with an average age of 84.47 years (SD 8.45) and 803 (22.1%) were men with an average age of 81.64 years (SD 10.08). The cumulative incidence of mortality was 69.38%. The cumulative mortality rate for 12 months was 33%. The annual mortality was 144.9/1000 patients/year. The 1-year mortality rate increased significantly by 2% per year (IRR 1.020, CI95% 1.008–1.033). The median overall survival was 886 days (CI95% 836–951). The probability of mortality density for a period of 10 years following a hip fracture was 16% for women and 25% for men (first 90 days). The SDR was 8.3 (CI95% 7.98–8.59). Variables that showed statistically significant association with mortality were aged over 75, masculine, institutionalization, mild to severe liver disease, chronic kidney disease, COPD, dementia, heart failure, diabetes, the Charlson Index > 2 , presence of vision disorders and hearing impairment, incontinence, and Downton scale. For the last 17 years, an increase of mortality for patients with hip fracture and a higher mortality rate in men than in women were observed. Institutionalization combined with comorbidities is associated with a higher mortality.

29 December 2011 in PLOS ONE
Verified
Journal Article
Open access
PDF file
IGIsidoro González-Álvaro
Isidoro González-Álvaro
AOAna M. Ortiz
Ana M. Ortiz
JAJosé María Alvaro-Gracia
José María Alvaro-Gracia
Santos CastañedaSantos Castañeda
Santos Castañeda
BDBelen Díaz-Sánchez
Belen Díaz-Sánchez
RGRosario García-Vicuña
Rosario García-Vicuña
Interleukin-15 (IL-15) is thought to be involved in the physiopathological mechanisms of RA and it can be detected in the serum and the synovial fluid of inflamed joints in patients with RA but not in patients with osteoarthritis or other inflammatory joint diseases. Therefore, the objective of this work is to analyse whether serum IL-15 (sIL-15) levels serve as a biomarker of disease severity in patients with early arthritis (EA). Data from 190 patients in an EA register were analysed (77.2% female; median age 53 years; 6-month median disease duration at entry). Clinical and treatment information was recorded systematically, especially the prescription of disease modifying anti-rheumatic drugs. Two multivariate longitudinal analyses were performed with different dependent variables: 1) DAS28 and 2) a variable reflecting intensive treatment. Both included sIL-15 as predictive variable and other variables associated with disease severity, including rheumatoid factor (RF) and anti-cyclic citrullinated peptide antibodies (ACPA). Of the 171 patients (638 visits analysed) completing the follow-up, 71% suffered rheumatoid arthritis and 29% were considered as undifferentiated arthritis. Elevated sIL-15 was detected in 29% of this population and this biomarker did not overlap extensively with RF or ACPA. High sIL-15 levels (β Coefficient [95% confidence interval]: 0.12 [0.06–0.18]; p<0.001) or ACPA (0.34 [0.01–0.67]; p = 0.044) were significantly and independently associated with a higher DAS28 during follow-up, after adjusting for confounding variables such as gender, age and treatment. In addition, those patients with elevated sIL-15 had a significantly higher risk of receiving intensive treatment (RR 1.78, 95% confidence interval 1.18–2.7; p = 0.007). Patients with EA displaying high baseline sIL-15 suffered a more severe disease and received more intensive treatment. Thus, sIL-15 may be a biomarker for patients that are candidates for early and more intensive treatment.

1 April 1997 in Calcified Tissue International
Verified
Journal Article
Closed access
PDF file
SCS. Castañeda
S. Castañeda
LCLoreto Carmona
Loreto Carmona
ICI. Carvajal
I. Carvajal
RAR. Arranz
R. Arranz
ADA. Díaz
A. Díaz
AGA. García-Vadillo
A. García-Vadillo

27 February 2017 in Rheumatology International
Verified
Journal Article
Open access
PDF file
ILIrene Llorente
Irene Llorente
LMLeticia Merino
Leticia Merino
AOAna M. Ortiz
Ana M. Ortiz
EEEugenio Escolano
Eugenio Escolano
SGSaturnino González-Ortega
Saturnino González-Ortega
IGIsidoro González-Álvaro
Isidoro González-Álvaro
Since the previous studies showed that anti-citrullinated protein antibodies (ACPA) can induce osteoclasts differentiation and activation, even before arthritis onset, the aim of our study was to determine whether ACPA-positivity is associated with lower bone mineral density (BMD) at baseline visit of a register of early arthritis (EA) patients. The study population comprised 578 patients (80% females) from our EA clinic with a median disease duration, 5.1 months (p25–p75: 6–8); median age, 53.6 years (41.9–66.1), 38% ACPA-positive, and 55% fulfilling 2010 criteria for rheumatoid arthritis. BMD was measured using dual X-ray absorptiometry at lumbar spine, hip, and metacarpophalangeal (MCP) joints of the non-dominant hand to evaluate both systemic and juxta-articular bone mass. ACPA titers were determined through enzyme immunoassay. The effect of ACPA on BMD was analyzed using multivariable analysis based on generalized linear models adjusted for various confounders. ACPA-positive patients showed lower bone mass at lumbar spine and hip, but no differences were observed at MCP joints compared to ACPA-negative patients. However, ACPA-positive patients displayed higher disease activity and disability than ACPA-negative patients. After adjustment for gender, age, body mass index, and other bone-related variables, the presence of ACPA remained significantly associated with lower BMD at the lumbar spine, femoral neck, and hip but not at MCP joints. Disease activity was not associated with baseline bone mass. Our data reinforce the previous preclinical findings suggesting that the systemic bone loss detected at the initial phases of early ACPA-positive arthritis is independent of inflammatory status and, therefore, could be mediated by ACPA.

31 December 2011 in Reumatología Clínica
Verified
Journal Article
Closed access
LELluís Pérez Edo
Lluís Pérez Edo
ARAlberto Alonso Ruiz
Alberto Alonso Ruiz
DVDaniel Roig Vilaseca
Daniel Roig Vilaseca
AVAlberto García Vadillo
Alberto García Vadillo
NGNuria Guañabens Gay
Nuria Guañabens Gay
ELEstíbaliz Loza
Estíbaliz Loza

1 May 2017 in Journal of Clinical Lipidology
Verified
Journal Article
Open access
CGCarmen García-Gómez
Carmen García-Gómez
MMMaria A. Martín-Martínez
Maria A. Martín-Martínez
Santos CastañedaSantos Castañeda
Santos Castañeda
FSFernando Sanchez-Alonso
Fernando Sanchez-Alonso
MUMiren Uriarte-Ecenarro
Miren Uriarte-Ecenarro
JMJosé A. Miranda-Filloy
José A. Miranda-Filloy
Plasma concentrations of lipoprotein (a) (Lp(a)), a lipoprotein with atherogenic and thrombogenic properties, have a strong genetic basis, although high concentrations of Lp(a) have also been reported in the context of inflammation, as in rheumatoid arthritis (RA). Few studies evaluate the impact of biologic therapies (BT) on Lp(a) in RA, taking into account that with these new therapies a better control of inflammation is achieved. The aim of the study was to evaluate the plasma concentrations of Lp(a) in Spanish RA patients on BT attending rheumatology outpatient clinics. Baseline analysis of the CARdiovascular in rheuMAtology project, a 10-year prospective study, evaluating the risk of cardiovascular events in RA and other forms of inflammatory arthritis. RA patients were classified according to treatment: no biologic, anti-tumor necrosis factor, anti-interleukin-6 receptor tocilizumab (TCZ), and other biologic (rituximab or abatacept). A model of linear multivariate regression was built in which the dependent variable was Lp(a) concentration and the explanatory variable was BT. The model was adjusted for confounding factors. Seven hundred and seventy-five RA patients were analyzed. Plasma concentrations of total cholesterol and triglyceride were significantly higher in TCZ-treated patients. Nevertheless, no significant difference in the atherogenic index between TCZ-treated patients and patients without BT was found. After adjusting for confounding factors, patients with BT had lower concentrations of Lp(a) than those without BT; however, only TCZ-treated patients achieved statistically significant differences (β: -0.303, 95% confidence interval: -0.558 to -0.047; P = .02). RA patients treated with TCZ show lower plasma concentrations of Lp(a) compared with patients without BT.